News

This regimen is indicated for adults with unresectable locally advanced or metastatic human epidermal growth factor 2-positive (HER2+) disease following induction treatment. The regulatory decision introduces an oral

The initiative represents the first time 10x Genomics has widened its clinical research scope past solid tumours to include haematologic malignancies. Under the partnership, the organisations will carry

The financing arrangement extends the biotechnology company’s projected operational cash runway into the third quarter of 2028 when combined with existing reserves, with further drawdowns potentially extending funding

The renewed arrangement will see Cognizant combine its life sciences sector knowledge with technical services to aid Gilead’s ongoing development and operational processes. The joint work is intended

Exparel (bupivacaine liposome injectable suspension), is a long-acting local analgesic used for postsurgical pain management. Under the agreement, Pacira will obtain an undisclosed upfront payment, alongside a supply

The 18-storey, 570,000ft² facility at 290 Binney Street features ten floors of interconnecting laboratories equipped with continuous automation, robotics, and agentic AI. Combined with the company’s genomic medicine

Jaypirca is a non-covalent Bruton tyrosine kinase (BTK) inhibitor and is administered orally as 50mg or 100mg tablets to achieve a daily 200mg dose. The regulatory decision is

The facility will be constructed in the New Albany International Business Park. This investment adds to more than $7bn spent by the company on pharmaceutical research, development, and

The therapy is indicated to improve functional capacity and symptoms. The regulatory decision was supported by findings from the double-blind, randomised Phase III SCOUT-HCM trial, which assessed the